YMRC
ADAP

Yorktown Management & Research Company’s Adaptimmune Therapeutics ADAP Stock Holding History

Yorktown Management & Research Company’s Portfolio ADAP Stock Details ADAP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-32,000
Closed -$261K – 291
2016
Q2 		$261K Buy
+32,000
New +$301K 0.06% 211

Other funds holding ADAP

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Yorktown Management & Research Company's ADAP Position: Q3 2016 in Review

Yorktown Management & Research Company sold out of Adaptimmune Therapeutics (ADAP) in Q3 2016, closing a stake of 32,000 shares — an estimated $261K sold.

Yorktown Management & Research Company first reported a position in ADAP in Q2 2016 and held it in 1 quarter. The position peaked at $261K in Q2 2016. 46 funds tracked by Wall St. Rank hold ADAP as of Q3 2016.

  • Yorktown Management & Research Company reported no remaining Adaptimmune Therapeutics position as of Q3 2016 after selling out during the quarter.
  • Yorktown Management & Research Company sold 32,000 Adaptimmune Therapeutics shares in Q3 2016, an estimated $261K.
  • Yorktown Management & Research Company first reported a position in Adaptimmune Therapeutics in Q2 2016 and held it in 1 quarter.
  • Yorktown Management & Research Company's Adaptimmune Therapeutics position peaked at $261K in Q2 2016.
  • 46 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q3 2016.

Based on Yorktown Management & Research Company's 13F filing for Q3 2016, filed 31 Oct 2016.